{"denoms":[{"counts":[{"groupId":"BG000","value":"49"}],"units":"Participants"}],"groups":[{"description":"Ribociclib 600 mg administered orally daily for 21 days followed by 7 days off in 28-day treatment cycle in combination with Letrozole 2.5 mg administered orally daily for 28 days. Treatment continues until disease progression or unacceptable toxicity.","id":"BG000","title":"Ribociclib and Letrozole"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"20-29"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"30-39"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"40-49"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"50-59"},{"measurements":[{"groupId":"BG000","value":"17"}],"title":"60-69"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"70-79"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"80-89"}],"title":"Age (Years)"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Black"},{"measurements":[{"groupId":"BG000","value":"44"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Declined to Report"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"38"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Declined to Report"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown"}],"title":"Ethnicity"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}],"title":"ECOG 0"},{"measurements":[{"groupId":"BG000","value":"21"}],"title":"ECOG 1"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Not Reported"}]}],"description":"ECOG 0 is fully active, able to carry on all pre-disease performance without restriction.\n\nECOG 1 is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.","paramType":"COUNT_OF_PARTICIPANTS","title":"Performance Status (ECOG)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44"}],"title":"Ovary"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Peritoneum"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Site of Disease","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"I"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"II"},{"measurements":[{"groupId":"BG000","value":"36"}],"title":"III"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"IV"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Not Reported"}]}],"description":"FIGO stage at diagnosis was reported by each participant institution according to their standard practice. In general, a higher FIGO stage indicates more advanced disease.","paramType":"COUNT_OF_PARTICIPANTS","title":"FIGO Stage at Diagnosis (ohr)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"46"}],"title":"Yes"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Surgery","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"48"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Yes"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Radiation Therapy (ohr)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"46"}],"title":"Yes"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Any Prior Immunologic/Chemo/Hormonal/Biologic/Antiangiogenic/Other therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"4"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"5"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"6 or more"}]}],"description":"Any immunologic/chemo/hormonal/biologic/antiangiogenic/other therapy reported by participation sites, where a line of therapy was defined by the participation sites' standards.","paramType":"COUNT_OF_PARTICIPANTS","title":"Lines of Prior Therapy (ohr)","unitOfMeasure":"Participants"}]}